These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 18005449

  • 21. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B.
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [Abstract] [Full Text] [Related]

  • 22. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
    Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M.
    Int J Geriatr Psychiatry; 2000 Jun; 15(6):506-14. PubMed ID: 10861916
    [Abstract] [Full Text] [Related]

  • 23. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R, Abordaje Síntomas Negativos Esquizofrenia Group.
    J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
    [Abstract] [Full Text] [Related]

  • 24. Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia - data from the OPTiMiSE trial.
    Baandrup L, Allerup P, Nielsen MØ, Bak N, Düring SW, Leucht S, Galderisi S, Mucci A, Bucci P, Arango C, Díaz-Caneja CM, Dazzan P, McGuire P, Demjaha A, Ebdrup BH, Kahn RS, Glenthøj BY.
    Psychiatry Res; 2020 Jul; 289():112970. PubMed ID: 32438207
    [Abstract] [Full Text] [Related]

  • 25. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
    Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA.
    Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
    [Abstract] [Full Text] [Related]

  • 26. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
    Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR.
    Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
    [Abstract] [Full Text] [Related]

  • 27. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [Abstract] [Full Text] [Related]

  • 28. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
    Stauffer VL, Sniadecki JL, Piezer KW, Gatz J, Kollack-Walker S, Hoffmann VP, Conley R, Durell T.
    BMC Psychiatry; 2010 Nov 03; 10():89. PubMed ID: 21047395
    [Abstract] [Full Text] [Related]

  • 29. Psychotic features in chronic posttraumatic stress disorder and schizophrenia: comparative severity.
    Hamner MB, Frueh BC, Ulmer HG, Huber MG, Twomey TJ, Tyson C, Arana GW.
    J Nerv Ment Dis; 2000 Apr 03; 188(4):217-21. PubMed ID: 10789998
    [Abstract] [Full Text] [Related]

  • 30. French version validation of the psychotic symptom rating scales (PSYRATS) for outpatients with persistent psychotic symptoms.
    Favrod J, Rexhaj S, Ferrari P, Bardy S, Hayoz C, Morandi S, Bonsack C, Giuliani F.
    BMC Psychiatry; 2012 Sep 28; 12():161. PubMed ID: 23020603
    [Abstract] [Full Text] [Related]

  • 31. Positive and negative symptoms in the psychoses: multidimensional scaling of SAPS and SANS items.
    Minas IH, Stuart GW, Klimidis S, Jackson HJ, Singh BS, Copolov DL.
    Schizophr Res; 1992 Dec 28; 8(2):143-56. PubMed ID: 1457393
    [Abstract] [Full Text] [Related]

  • 32. Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model.
    Anderson AE, Reise SP, Marder SR, Mansolf M, Han C, Bilder RM.
    Innov Clin Neurosci; 2017 Dec 01; 14(11-12):41-53. PubMed ID: 29410936
    [Abstract] [Full Text] [Related]

  • 33. Symptom dimensions of the psychotic symptom rating scales in psychosis: a multisite study.
    Woodward TS, Jung K, Hwang H, Yin J, Taylor L, Menon M, Peters E, Kuipers E, Waters F, Lecomte T, Sommer IE, Daalman K, van Lutterveld R, Hubl D, Kindler J, Homan P, Badcock JC, Chhabra S, Cella M, Keedy S, Allen P, Mechelli A, Preti A, Siddi S, Erickson D.
    Schizophr Bull; 2014 Jul 01; 40 Suppl 4(Suppl 4):S265-74. PubMed ID: 24936086
    [Abstract] [Full Text] [Related]

  • 34. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.
    Potkin SG, Phiri P, Szegedi A, Zhao J, Alphs L, Cazorla P.
    Schizophr Res; 2013 Nov 01; 150(2-3):442-9. PubMed ID: 24075603
    [Abstract] [Full Text] [Related]

  • 35. Cognitive behaviour therapy for psychotic symptoms: a randomized controlled effectiveness trial.
    Kråkvik B, Gråwe RW, Hagen R, Stiles TC.
    Behav Cogn Psychother; 2013 Oct 01; 41(5):511-24. PubMed ID: 23635846
    [Abstract] [Full Text] [Related]

  • 36. The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.
    Breier A, Berg PH.
    Biol Psychiatry; 1999 Aug 01; 46(3):361-4. PubMed ID: 10435201
    [Abstract] [Full Text] [Related]

  • 37. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman JA.
    Psychiatr Serv; 2001 Nov 01; 52(11):1510-4. PubMed ID: 11684748
    [Abstract] [Full Text] [Related]

  • 38. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
    Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM.
    Schizophr Res; 2003 Jun 01; 61(2-3):303-14. PubMed ID: 12729882
    [Abstract] [Full Text] [Related]

  • 39. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
    Ruberg SJ, Chen L, Stauffer V, Ascher-Svanum H, Kollack-Walker S, Conley RR, Kane J, Kinon BJ.
    BMC Psychiatry; 2011 Feb 09; 11():23. PubMed ID: 21306626
    [Abstract] [Full Text] [Related]

  • 40. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders.
    Helldin L, Kane JM, Karilampi U, Norlander T, Archer T.
    Schizophr Res; 2007 Jul 09; 93(1-3):160-8. PubMed ID: 17395430
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.